Quentin Liu

List of Publications by Year
in descending order

102 papers	8,585 citations	109321 35 h-index	46799 89 g-index
106 all docs	106 docs citations	106 times ranked	19298 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death and Disease, 2018, 8, e2569-e2569.	6.3	199
3	Auroraâ€A Kinase: A Potent Oncogene and Target for Cancer Therapy. Medicinal Research Reviews, 2016, 36, 1036-1079.	10.5	181
4	The Splicing Factor RBM4 Controls Apoptosis, Proliferation, and Migration to Suppress Tumor Progression. Cancer Cell, 2014, 26, 374-389.	16.8	166
5	Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy, 2012, 8, 1798-1810.	9.1	155
6	Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nature Communications, 2016, 7, 10180.	12.8	142
7	Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells. Journal of Clinical Investigation, 2019, 129, 1030-1046.	8.2	138
8	The Philadelphia chromosome in leukemogenesis. Chinese Journal of Cancer, 2016, 35, 48.	4.9	137
9	Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis. Molecular Cancer, 2020, 19, 138.	19.2	122
10	The Mitotic Kinase Aurora-A Induces Mammary Cell Migration and Breast Cancer Metastasis by Activating the Cofilin-F-actin Pathway. Cancer Research, 2010, 70, 9118-9128.	0.9	108
11	RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. Journal of Clinical Investigation, 2021, 131, .	8.2	103
12	A splicing isoform of TEAD4 attenuates the Hippoâ€“YAP signalling to inhibit tumour proliferation. Nature Communications, 2016, 7, ncomms11840.	12.8	80
13	Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget, 2015, 6, 6326-6340.	1.8	76
14	Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget, 2014, 5, 9118-9132.	1.8	71
15	Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation. PLoS ONE, 2014, 9, e105381.	2.5	69
16	Oncogenic AURKA-enhanced N6-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. Cell Research, 2021, 31, 345-361.	12.0	68
17	IKKÎ± restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nature Communications, 2014, 5, 3661.	12.8	67
18	Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget, 2015, 6, 3963-3976.	1.8	67

#	Article	IF	Citations
19	Practice of traditional Chinese medicine for psycho-behavioral intervention improves quality of life in cancer patients: A systematic review and meta-analysis. Oncotarget, 2015, 6, 39725-39739.	1.8	67
20	Aurora-A Identifies Early Recurrence and Poor Prognosis and Promises a Potential Therapeutic Target in Triple Negative Breast Cancer. PLoS ONE, 2013, 8, e56919.	2.5	66
21	SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance. EBioMedicine, 2018, 38, 113-126.	6.1	66
22	Estrogen receptor Î² upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. Cell Death and Disease, 2018, 9, 1120.	6.3	63
23	Prognostic value of autophagy related proteins ULK1, Beclin 1, ATG3, ATG5, ATG7, ATG9, ATG10, ATG12, LC3B and p62/SQSTM1 in gastric cancer. American Journal of Translational Research (discontinued), 2016, 8, 3831-3847.	0.0	62
24	Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma. Nature Medicine, 2018, 24, 154-164.	30.7	58
25	Salinomycin exerts anticancer effects on human breast carcinoma MCF-7 cancer stem cells via modulation of Hedgehog signaling. Chemico-Biological Interactions, 2015, 228, 100-107.	4.0	52
26	A Novel Small-Molecule Aurora Kinase Inhibitor Attenuates Breast Tumorâ€“Initiating Cells and Overcomes Drug Resistance. Molecular Cancer Therapeutics, 2014, 13, 1991-2003.	4.1	51
27	Ku80 cooperates with CBP to promote COX-2 expression and tumor growth. Oncotarget, 2015, 6, 8046-8061.	1.8	50
28	p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis. Carcinogenesis, 2017, 38, 1092-1103.	2.8	49
29	Activation of Aurora A kinase increases YAP stability via blockage of autophagy. Cell Death and Disease, 2019, 10, 432.	6.3	47
30	Differentiation therapy: a promising strategy for cancer treatment. Chinese Journal of Cancer, 2016, 35, 3.	4.9	44
31	SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduction and Targeted Therapy, 2021, 6, 108.	17.1	44
32	PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. Oncogene, 2021, 40, 1375-1389.	5.9	44
33	SOX1 down-regulates Î²-catenin and reverses malignant phenotype in nasopharyngeal carcinoma. Molecular Cancer, 2014, 13, 257.	19.2	43
34	Prediction of competing endogenous RNA coexpression network as prognostic markers in AML. Aging, 2019, 11, 3333-3347.	3.1	43
35	Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in tripleâ€negative breast cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 6442-6453.	3.6	42
36	Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors. European Journal of Medicinal Chemistry, 2014, 78, 65-71.	5.5	39

#	Article	IF	Citations
37	Cancer and stress: NextGen strategies. Brain, Behavior, and Immunity, 2021, 93, 368-383.	4.1	39
38	hnRNPA2/B1 activates cyclooxygenaseâ€2 and promotes tumor growth in human lung cancers. Molecular Oncology, 2016, 10, 610-624.	4.6	36
39	XAB2 functions in mitotic cell cycle progression via transcriptional regulation of CENPE. Cell Death and Disease, 2016, 7, e2409-e2409.	6.3	33
40	Aurora kinase A suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cells. Oncotarget, 2014, 5, 7498-7511.	1.8	32
41	Nuclear Aurora kinase A switches m6A reader YTHDC1 to enhance an oncogenic RNA splicing of tumor suppressor RBM4. Signal Transduction and Targeted Therapy, 2022, 7, 97.	17.1	32
42	Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation. Scientific Reports, 2016, 6, 35533.	3.3	29
43	Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino- N -(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents. European Journal of Medicinal Chemistry, 2016, 108, 644-654.	5.5	28
44	Plasma miR-124 Is a Promising Candidate Biomarker for Human Intracerebral Hemorrhage Stroke. Molecular Neurobiology, 2018, 55, 5879-5888.	4.0	27
45	Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer. Cellular Physiology and Biochemistry, 2017, 44, 1051-1063.	1.6	26
46	USP42 drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis. Cell Death and Differentiation, 2021, 28, 2482-2498.	11.2	26
47	Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells. Oncotarget, 2015, 6, 21557-21571.	1.8	25
48	Transcriptomic but not genomic variability confers phenotype of breast cancer stem cells. Cancer Communications, 2018, 38, 1-16.	9.2	25
49	CRISPR/Cas9 screening identifies a kinetochoreâ€microtubule dependent mechanism for Auroraâ€A inhibitor resistance in breast cancer. Cancer Communications, 2021, 41, 121-139.	9.2	25
50	Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell Death and Differentiation, 2022, 29, 2247-2261.	11.2	24
51	Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors. European Journal of Medicinal Chemistry, 2018, 157, 1361-1375.	5.5	23
52	Using plasma cellâ€free DNA to monitor the chemoradiotherapy course of cervical cancer. International Journal of Cancer, 2019, 145, 2547-2557.	5.1	23
53	The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncology, 2020, 104, 104640.	1.5	23
54	cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy. Molecular Therapy, 2022, 30, 1006-1017.	8.2	23

#	Article	IF	Citations
55	Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. Journal of Translational Medicine, 2016, 14, 270.	4.4	22
56	Photodynamic therapy with methyl-5-aminolevulinate for basal cell carcinoma: A systematic review and meta-analysis. Photodiagnosis and Photodynamic Therapy, 2020, 29, 101667.	2.6	22
57	Antibodies against Epsteinâ€“Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology. Journal of General Virology, 2008, 89, 1152-1158.	2.9	20
58	Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers. Oncotarget, 2014, 5, 9349-9361.	1.8	20
59	Synthesis and biological evaluation of aurora kinases inhibitors based on N -trisubstituted pyrimidine scaffold. European Journal of Medicinal Chemistry, 2018, 145, 805-812.	5.5	20
60	CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. Cell Death and Disease, 2021, 12, 740.	6.3	19
61	miR-200c Accelerates Hepatic Stellate Cell-Induced Liver Fibrosis via Targeting the FOG2/PI3K Pathway. BioMed Research International, 2017, 2017, 1-8.	1.9	18
62	A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD). Cancer Cell International, 2021, 21, 294.	4.1	18
63	Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1Î±, refines relapse risk and predicts poor outcome for breast cancer. Oncology Reports, 2014, 32, 1101-1107.	2.6	17
64	A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells. International Journal of Oncology, 2015, 46, 2488-2496.	3.3	17
65	RUVBL1-ITFG1 interaction is required for collective invasion in breast cancer. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1788-1800.	2.4	17
66	Downregulation of ATOH8 induced by EBV-encoded LMP1 contributes to the malignant phenotype of nasopharyngeal carcinoma. Oncotarget, 2016, 7, 26765-26779.	1.8	17
67	MRNIP condensates promote DNA double-strand break sensing and end resection. Nature Communications, 2022, 13, 2638.	12.8	17
68	Aurora kinase inhibitor restrains STAT5â€activated leukemic cell proliferation by inducing mitochondrial impairment. Journal of Cellular Physiology, 2020, 235, 8358-8370.	4.1	15
69	Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma. Signal Transduction and Targeted Therapy, 2021, 6, 333.	17.1	14
70	Targeting NF-ÎºB/AP-2Î² signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells. American Journal of Cancer Research, 2017, 7, 13-27.	1.4	14
71	ATO/ATRA/Anthracycline-Chemotherapy Sequential Consolidation Achieves Long-Term Efficacy in Primary Acute Promyelocytic Leukemia. PLoS ONE, 2014, 9, e104610.	2.5	13
72	Quantitative Lysine Reactivity Profiling Reveals Conformational Inhibition Dynamics and Potency of Aurora A Kinase Inhibitors. Analytical Chemistry, 2019, 91, 13222-13229.	6.5	13

#	Article	IF	Citations
73	Nuclear Aurora kinase A triggers programmed deathâ€ligand 1â€mediated immune suppression by activating MYC transcription in tripleâ€negative breast cancer. Cancer Communications, 2021, 41, 851-866.	9.2	12
74	UHRF1 suppression promotes cell differentiation and reduces inflammatory reaction in anaplastic thyroid cancer. Oncotarget, 2018, 9, 31945-31957.	1.8	12
75	Cancer Stem Cells Therapeutic Target Database: The First Comprehensive Database for Therapeutic Targets of Cancer Stem Cells. Stem Cells Translational Medicine, 2017, 6, 331-334.	3.3	10
76	The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis. BMC Cancer, 2020, 20, 393.	2.6	10
77	Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells. Oncotarget, 2016, 7, 44171-44184.	1.8	9
78	New insights from the widening homogeneity perspective to target intratumor heterogeneity. Cancer Communications, 2018, 38, 1-7.	9.2	9
79	Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Journal of Oncology, 2020, 2020, 1-10.	1.3	9
80	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. Medicine (United States), 2020, 99, e21273.	1.0	9
81	Cancer cell immune mimicry delineates onco-immunologic modulation. IScience, 2021, 24, 103133.	4.1	9
82	Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies. Oncotarget, 2016, 7, 58586-58594.	1.8	9
83	Cell cycle protein Bora serves as a novel poor prognostic factor in multiple adenocarcinomas. Oncotarget, 2017, 8, 43838-43852.	1.8	9
84	Inhibition of AURKA kinase activity suppresses collective invasion in a microfluidic cell culture platform. Scientific Reports, 2017, 7, 2973.	3.3	8
85	Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma. Cancer Medicine, 2019, 8, 5673-5686.	2.8	8
86	Psychoneuroimmunology goes East: Development of the PNIRS affiliate and its expansion into PNIRS. Brain, Behavior, and Immunity, 2020, 88, 75-87.	4.1	8
87	Virus infection facilitates the development of severe pneumonia in transplant patients with hematologic malignancies. Oncotarget, 2016, 7, 53930-53940.	1.8	7
88	Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer. BMC Cancer, 2021, 21, 1203.	2.6	7
89	The prognostic landscape of interactive biological processes presents treatment responses in cancer. EBioMedicine, 2019, 41, 120-133.	6.1	6
90	Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition. Cell Death and Disease, 2021, 12, 893.	6.3	6

#	Article	IF	Citations
91	A Novel Aurora Kinase Inhibitor Attenuates Leukemic Cell Proliferation Induced by Mesenchymal Stem Cells. Molecular Therapy - Oncolytics, 2020, 18, 491-503.	4.4	5
92	SOX1 promotes differentiation of nasopharyngeal carcinoma cells by activating retinoid metabolic pathway. Cell Death and Disease, 2020, 11, 331.	6.3	5
93	A Temporal PROTAC Cocktailâ€Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells. Advanced Science, 2022, 9, .	11.2	5
94	Loss of MYC and E-box3 binding contributes to defective MYC-mediated transcriptional suppression of human MC-let-7a-1~let-7d in glioblastoma. Oncotarget, 2016, 7, 56266-56278.	1.8	4
95	Longitudinal whole-genome sequencing reveals the evolution of MPAL. Cancer Genetics, 2020, 240, 59-65.	0.4	3
96	Allele frequency deviation (AFD) as a new prognostic model to predict overall survival in lung adenocarcinoma (LUAD). Cancer Cell International, 2021, 21, 451.	4.1	3
97	A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone. PLoS ONE, 2022, 17, e0265551.	2.5	3
98	6 versus 12â€Šmonths of adjuvant trastuzumab in HER2+ early breast cancer. Medicine (United States), 2021, 100, e24995.	1.0	2
99	Discovery and biological evaluation of a smallâ€molecule inhibitor of <scp>CRM1</scp> that suppresses the growth of tripleâ€negative breast cancer cells. Traffic, 2021, 22, 221-229.	2.7	2
100	Measurable Krukenberg tumor is preferably characterized as a non-target lesion in the clinical evaluation ofï¿½gastric cancer therapeutics: A case report. Molecular and Clinical Oncology, 2018, 9, 622-628.	1.0	0
101	A tolerability and safety analysis of adding granulocyte-macrophage colony-stimulating factor to local radiotherapy in a case series of seven patients with thoracic cancer. Annals of Palliative Medicine, 2021, 10, 4193-4200.	1.2	0
102	Use of the mitotic kinase aurora-A activation to predict outcome for primary duodenal adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 4131-4131.	1.6	0